Ludek, Pour <br/><br/>
Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.  [electronic resource] 

 -  European journal of haematology  Apr 2010 
 - 332-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0609 
<br/><br/><label>Standard No.: </label>10.1111/j.1600-0609.2009.01396.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Bone Marrow--metabolism<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Female<br/>Hepatocyte Growth Factor--blood<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--blood<br/>Neovascularization, Pathologic--blood<br/>Pyrazines--administration & dosage<br/>Recurrence<br/>Thrombospondins--metabolism